Simultaneous UV Spectrophotometric Methods for Estimation of Cefixime Trihydrate and Ofloxacin in Bulk and Tablet Dosage Form

 

Audumbar Mali1*, Santosh Jadhav1, Rahul Gorad2, Aamer Quazi2, Ritesh Bathe1, Manojkumar Patil1, Ashpak Tamboli3

1Department of Pharmaceutics, Sahyadri College of Pharmacy, Methwade, Sangola-413307, Solapur, Maharashtra, India.

2Department of Pharmaceutics, ASPM’S K. T. Patil College of Pharmacy, Osmanabad-413501, Maharashtra, India.

3Department of Pharmaceutical Chemistry, Sahyadri College of Pharmacy, Methwade, Sangola-413307, Solapur, Maharashtra, India.

*Corresponding Author E-mail: maliaudu442@gmail.com

 

ABSTRACT:

Simple, precise, economical, fast and reliable two UV methods have been developed for the simultaneous estimation of Cefixime Trihydrate and Ofloxacin in bulk and pharmaceutical dosage form. Method A is Absorbance maxima method, which is based on measurement of absorption at maximum wavelength of 287 nm and 296 nm for Cefixime Trihydrate and Ofloxacin respectively. Method B is area under curve (AUC), in the wavelength range of 265-301 nm for Cefixime Trihydrate and277-320nm for Ofloxacin. Linearity for detector response was observed in the concentration range of 5-25μg/ml for Cefixime Trihydrate and 5-25 μg/ml for Ofloxacin. The accuracy of the methods was assessed by recovery studies and was found to be 98.83% and 100.12% for Cefixime Trihydrate and 102.71 % and 99.01 % Ofloxacin by using method A and B respectively. The developed method was validated with respect to linearity, accuracy (recovery), precision and specificity. The results were validated statistically as per ICH Q2 R1guideline and were found to be satisfactory. The proposed methods were successfully applied for the determination of for Cefixime Trihydrate and Ofloxacin in commercial pharmaceutical dosage form.

 

KEY WORDS: Cefixime Trihydrate, Ofloxacin, Simultaneous estimation, Accuracy, Absorbance maxima method, Area under curve.

 

 


 

1. INTRODUCTION:

Cefixime Trihydrate (CEF) chemically is (6R, 7R)-7-[[(z)-2-(2-aminothiazol-4-yl) 2-[(carboxy methoxy) imino] acetyl]-amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo [4.2.0] oct-2ene-2-carboxylic acid. It is an oral third generation of cephalosporin and is used as an antibacterial and especially against gram negative, gram positive and anaerobic bacteria pathogens including β- lactamase producing strains. It consists of high affinity for penicillin binding proteins with deceitful site of activity. It acts by inhibition of bacterial cell-wall synthesis. It is clinically used in the treatment of susceptible infections including gonorrhea, otitis media, pharyngitis, lower respiratory-tract infections such as bronchitis and urinary-tract infections.1-4

 

 

Fig. 1: chemical structure of Cefixime Trihydrate

 

Ofloxacin (OFL) a fluorinated carboxyaquinolone, chemically is a racemate (+) -9-fluro-2, 3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido [1,2,3-de]-1,4-benzoxazine-6-carboxylic acid. It is a synthetic broad spectrum antibacterial agent official in BP, USP and EP. Ofloxacin have much greater antibacterial activity towards urinary tract infections. It acts by inhibiting DNA gyrase of microorganisms.5-8

 

Fig. 2: chemical structure of Ofloxacin

 

A survey of pertinent literature revealed thatin estimation of individual9-11 as well as combination of Cefixime Trihydrate and Ofloxacin. Simultaneous determinations of Cefixime Trihydrateand Ofloxacindosage form were also reported like     HPLC12,13, RP-HPLC14-16, HPTLC17 and UV-Spectroscopy18-21. Therefore an attempt was made to develop a new rapid and sensitive UV Spectrophotometric method and to validate as per ICH-guidelines. A comprehensive literature research reveals the lack of a Spectrophotometric analytical method for simultaneous estimation of Cefixime Trihydrate and Ofloxacin in pharmaceutical formulations. A successful attempt was made to develop accurate, precise and simple method of analysis for estimation of both the drugs in combined dosage form.

 

2. MATERIALS AND METHODS:

2.1 Apparatus and instrumentation:-

A Shimadzu 1800 UV/VIS double beam spectrophotometer with 1cm matched quartz cells was used for all spectral measurements. Single Pan Electronic balance (Contech, CA 223, India) was used for weighing purpose. Sonication of the solutions was carried out using an Ultrasonic Cleaning Bath (Spectra lab UCB 40, India).Calibrated volumetric glassware (Borosil®) was used for the validation study.

 

2.2 Materials:-

Reference standard of Cefixime Trihydrate and Ofloxacin API were supplied as gift sample by Cipla Pharmaceutical Company, Goa, India. The commercial formulation ABIXIM*O with label claim 200 mg Cefixime Trihydrate and 200 mg Ofloxacin per tablet were purchased from local market Mangalwedha, Dist:-Solapur, Maharashtra, India.


 

 


 

Fig. 3: It shows λmax of Cefixime Trihydrate

 

Fig. 4: It shows λmax of Ofloxacin


 


 

 

2.3 Method development: -

2.3.1 Preparation of standard stock solution: -

Stock solution was prepared by diluting 10 mg of each drug in sufficient quantity of methanol in separate volumetric flask and volume was made up to 100 ml to get the concentrations of 100 μg/ml for each drug. Dilutions from stock solution were prepared in the range of 5-25 μg/ml for Cefixime Trihydrate and 5-25 μg/ml for Ofloxacin. Methanol was used as a blank solution.

 

2.3.2 Method A: Absorption Maxima Method: -

For the selection of analytical wavelength, standard solution of Cefixime Trihydrate and Ofloxacin were scanned in the spectrum mode from 400 nm to 200 nm separately. From the spectra of drug λmax of Cefixime Trihydrate, 287 nm [Fig.3], and λmax of Ofloxacin,296 nm [Fig.4], were selected for the analysis. Aliquots of standard stock solution were made and calibration curve was plotted.22, 23

 

2.3.3 Simultaneous estimation of Cefixime Trihydrate and Ofloxacin:

The wavelength maxima of Cefixime Trihydrate and Ofloxacin were determined and found to be 287 nm (λ1) and 296nm (λ2)respectively where there was no interference among the drugs. The overlain spectrum is shown in Fig.5.


 

 

Fig.5 Isobestic point of Cefixime Trihydrate and Ofloxacin

 

 


2.3.4 Method B: Area under Curve Method:

From the spectra of drug obtained after scanning of standard solution of Cefixime Trihydrate and Ofloxacin separately, area under the curve in the range of 265-301 nm and 277-320 nm was selected for the analysis. The calibration curve was prepared in the concentration range of 5-25 μg/ml for Cefixime Trihydrate and 5-25 μg/ml for Ofloxacin at their respective AUC range. Both drugs followed the Beer-Lambert’s law in the above mentioned concentration range. The calibration curves were plotted as absorbance against concentration of Cefixime Trihydrate and Ofloxacin. The coefficient of correlation (r), slope and intercept values of this method are given in Table 2.

 

Area calculation: (α+β) =

Where, α is area of portion bounded by curve data and a straight line connecting the start and end  point, β i  the area of portion bounded by a straight line connecting  the  start  and  end point on curve data and horizontal axis λ1 and λ2  are wavelength range start and end point of curve region.24-26

 

2.3.5 Application of the proposed methods for the determination of Cefixime Trihydrate and Ofloxacin in tablet dosage form:

For the estimation of drugs in the tablet formulation, 20 tablets were weighed and weight equivalent to 200 mg of Cefixime Trihydrate and 200mg of Ofloxacin was transferred to 100 ml volumetric flask and ultrasonicated for 20 minutes and volume was made up to the mark with methanol. The solution was then filtered through a Whatman filter paper (No.42). The filtrate was appropriately diluted further.

 

In Method-A, the concentration of Cefixime Trihydrate and Ofloxacin was determined by measuring the absorbance of the sample at 287nm and 296nm respectively in zero order spectrum modes. By using the calibration curve, the concentration of the sample solution was determined.

 

In Method-B, the concentration of Cefixime Trihydrate and Ofloxacin was determined by measuring area under curve in the range of 265-301 nm and 277-320nm. By using the calibration curve, the concentration of the sample solution was determined.


Table 1: Table shows Results of Analysis of Tablet Formulation

Method

Drug

Label Claim

mg

Sample Solution

Concentration (µg/ml)

Amount found (%)*±

% Recovery

%RSD

A

Cefixime Trihydrate

400 mg

20

101.36±1.04

98.83

 

0.7125

B

Cefixime Trihydrate

400 mg

20

98.54 ±0.91

100.12

A

Ofloxacin

400 mg

20

100.59 ±1.74

102.71

 

0.72361

B

Ofloxacin

400 mg

20

98.71 ±1.60

99.01

*n=3, % RSD = % Relative Standard Deviation.

 


 

Fig.6: It shows AUC of Cefixime Trihydrate

 

Fig.7: It shows AUC of Ofloxacin

 

 

 


3. Validation of the developed methods: [27-31]

The methods were validated with respect to accuracy, linearity, precision and selectivity.

 

3.1 Accuracy:

Accuracy of an analysis was determined by systemic error involved. Accuracy may often be expressed as% Recovery by the assay of known, added amount of analyte. It is measure of the exactness of the analytical method. Recovery studies carried out for both the methods by spiking standard drug in the powdered formulations 80%, 100%, 120% amount of each dosage content as per ICH guidelines.

 

3.2 Linearity:

The linearity of measurement was evaluated by analyzing different concentration of the standard solution of Cefixime Trihydrate and Ofloxacin. Result should be expressed in terms of correlation co-efficient.

 

3.3 Precision:

The reproducibility of the proposed method was determined by performing tablet assay at different time intervals (morning, afternoon and evening) on same day (Intra-day assay precision) and on three different days (Inter-day precision). Result of intra-day and inter-day precision is expressed in % RSD.

3.4 Sensitivity:

The limit of detection (LOD) and limit of quantitation (LOQ) were calculated by using the equations LOD = 3xσ/ S and LOQ = 10xσ/S, where σ is the standard deviation of intercept, S is the slope. The LOD and LOQ were found to be 0.6589 μg/ml and 1.9772 μg/ml respectively of Cefixime Trihydrate and 0.6794 μg/ml and 2.0382 μg/ml of Ofloxacin.

 

 

 

Fig.8: Calibration curve for Cefixime Trihydrate at 287 nm

 

 


Table 3: Results of drug content and analytical recovery of Cefixime Trihydrate and Ofloxacin

Excess drug added to the analyte (%)

Drug

% Recovery

% RSD

Method A

Method B

Method A

Method B

80

Cefixime Trihydrate

99.48

100.51

0.6570

0.6352

100

102.81

98.80

0.3589

0.8721

120

100.66

98.71

0.5873

0.6549

80

Ofloxacin

100.63

101.29

0.7487

0.5479

100

99.81

98.47

0.6589

0.6594

120

102.21

101.31

0.4470

0.7588

 

 

 

Table 4: Results of Intra-day and Inter-day Precision

Method

Drug

Intra-day Precision

Inter-day Precision

SD

%RSD

     SD

    %RSD

A

Cefixime Trihydrate

0.6910

0.5821

0.6783

0.3214

B

0.7048

0.4961

0.6691

0.1962

A

Ofloxacin

0.7691

0.8367

0.1013

0.1029

B

0.8793

0.6658

0.1852

0.1297

 

 

 


 

 

Fig.9: Calibration curve for Ofloxacin at 296 nm

 

 

 

 

Table 2: Optical Characteristics and Precision

Sr. No.

Parameter

Cefixime Trihydrate

Ofloxacin

1

λ range

200-400 nm

200-400nm

2

Regression Equation (y=mx+c)

Y=0.023x+

0.0171

Y=0.0214x+

0.0139

3

Measured wavelength

287 nm

296 nm

4

Linearity range

5-25µg/ml

5-25µg/ml

5

Slope

0.023

0.0214

6

Intercept

0.0171

0.0139

7

Correlation coefficient (R2)

0.9961

0.9973

8

Limit of Detection (LOD) µg/ml

0.6589

0.6794

9

Limit of Quantitation (LOQ)µg/ml

1.9772

2.0382

 

 

4. RESULTS AND DISCUSSION:-

The methods discussed in the present work provide a convenient and accurate way for analysis of Cefixime Trihydrateand Ofloxacin in its bulk and pharmaceutical dosage form. Absorbance maxima of Cefixime Trihydrate at 287nm and Ofloxacin at 296nm were selected for the analysis. Linearity for detector response was observed in the concentration range of 5-25 μg/ml for Cefixime Trihydrate and 5-25 μg/ml for Ofloxacin. Percent amount found for Cefixime Trihydrateand Ofloxacinin tablet analysis was found in the range of 101.36%, 98.54 and 100.59, 98.71 %respectively [Table 1]. Standard deviation and coefficient of variance for three determinations of tablet formulation, was found to be less than ± 2.0 indicating the precision of the methods. Accuracy of proposed methods was ascertained by recovery studies and the results are expressed as %recovery. % recovery for Cefixime Trihydrate and Ofloxacin was found in the range of 99.48 % and 100.63 % values of standard deviation and coefficient of variation was satisfactorily low indicating the accuracy of all the methods.% RSD for Intraday assay precision for Cefixime Trihydrate was found to be 0.5821 and 0.4961 for Method A and B, and for Ofloxacin, 0.8367 and 0.6658 for Method A and B. Interday assay precision for Cefixime Trihydrate was found to be 0.3214 and 0.1962 for Method A and B and for Ofloxacin 0.1029 and 0.1297 for Method A and B.The LOD and LOQ were found to be 0.6589 μg/ml and 1.9772 μg/ml respectively of Cefixime Trihydrate and 0.6794 μg/ml and 2.0382 μg/ml of Ofloxacin. Based on the results obtained, it is found that the proposed methods are accurate, precise, reproducible and economical and can be employed for routine quality control of Cefixime Trihydrate and Ofloxacin in bulk drug and its pharmaceutical dosage form.

 

5. CONCLUSION:

UV spectrophotometric methods for Cefixime Trihydrate and Ofloxacin were developed separately in bulk and tablet dosage form by, Absorbance maxima method and Area under curve method. Further, UV Spectrophotometric methods for the simultaneous estimation of Cefixime Trihydrate and Ofloxacin were in bulk and combined dosage form. The methods were validated as per ICH guidelines. The standard deviation and % RSD calculated for these methods are <2, indicating high degree of precision of the methods. The results of the recovery studies showed the high degree of accuracy of these methods. In conclusion, the developed methods are accurate, precise and selective and can be employed successfully for the estimation of Cefixime Trihydrate and Ofloxacin in bulk and pharmaceutical dosage form.

 

6. ACKNOWLEDGEMENT:

The authors are highly thankful to the Sahyadri College of Pharmacy, Methwade, Sangola, Solapur, Maharashtra, India for proving all the facilities to carry out the research work successfully.

 

7. REFERENCES:

1.       Audumbar Digambar Mali, Ritesh Bathe and Ashpak Tamboli. Simultaneous determination of Cefixime trihydrate and Ofloxacin in pharmaceutical dosage form by second order derivative UV spectrophotometry. International Journal of Advances in Pharmaceutical Analysis. 2015; 5(2): 42-46.

2.       Sivakumar C.V, Shubham Gupta, Amerendra K. Chandan, Chandrakala Gunturu, Meera Indracanti. Determination of Cefixime and Ofloxacin by Ratio Spectra and Zero Crossing Difference Spectrophotometry. International Journal of Pharmacy and Pharmaceutical Sciences. 2012; 4(3): 118-123.

3.       Audumbar Digambar Mali. Zero, First, Second Order Derivative and Area under Curve Spectrophotometric Methods for Determination of Cefixime Trihydrate in Pharmaceutical Formulation. International Journal of Pharmacy and Pharmaceutical Sciences. 2015; 7(6): 321-325.

4.       Mohammed Imran Anees, Mirza Shahed Baig and Ashwini Tathe. Determination of Cefixime and Moxifloxacin in Pharmaceutical Dosage Form by Simultaneous Equation and Area under Curve UV-Spectrophotometric Method. World Journal of Pharmacy and Pharmaceutical Sciences. 2015; 4(3):1 72-1179.

5.       VM. Gandhi, SB. Nair, C. Menezes and R. Narayan. Development of UV-Spectrophotometric Method forthe Quantitative Estimation of Ofloxacin and Ornidazole in Combined Liquid Oral Dosage Form by Simultaneous Equation Method. International Journal of Research in Pharmacy and Chemistry. 2013; 3(1): 6-11.

6.       Vijaya Vichare, Vrushali Tambe, S V Joshi, S N Dhole. New Simultaneous UV Visible Spectrophotometric Methods for Estimationof Ofloxacin and Ketorolac Tromethamine in Ophthalmic Dosage Form. Asian J. Pharm. Ana. 2013; 3(2): 53-57.

7.       Fegade JD, Mehta HP, Chaudhari RY, Patil VR. Simultaneous Spectrophotometric Estimation of Ofloxacin and Ketorolac Tromethamine in Ophthalmic Dosage Form. International Journal of Chem Tech Research. 2009;1(2): 189-194.

8.       M. Senthilraja. Simultaneous UV Spectrophotometric Method for the Estimation of Nitazoxanide and Ofloxacin in Combined Dosage Form. Research J. Pharm. and Tech. 2008; 1(4): 469-471.

9.       Md. Ahasan Ullah Nayon, Jeb-Un Nesa, Md. Nasir Uddin, Md. Shah Amran, Umme Bushra. Development and Validation of UV Spectrometric Method for the Determination of Cefixime Trihydrate in Bulk and Pharmaceutical Formulation. Asian Journal of Biomedical and Pharmaceutical Sciences. 2013; 3(2):1-5.

10.     Arun Kumar Dash, T. Siva Kishore, Loya Harika, Umadevi Kothapalli, Kothakota Vandana, Kishant Kumar Pradhan.A Validated UV-Spectrophotometric Method for the Estimation of Ofloxacin in Bulk and Pharmaceutical Dosage Form. International Journal of Pharmaceutical and Biological Archives. 2011; 2(4):1157-1161.

11.     Rajan V. Rele. UV spectrophotometric estimation of ofloxacin by area under curve methodsin bulk and pharmaceutical dosage form. Pelagia Research Library Der Pharmacia Sinica. 2015: 6(9): 39-43.

12.     Arshad HM, Gauhar S, Bano R, Muhammad IN. Development of HPLC-UV method for analysis of cefixime in raw materials and capsule. Jordan Journal of Pharmaceutical Sciences. 2009; 2(1): 53-65.

13.     Kraas E, Hirrle A. Determination of ofloxacin in biological fluidsusing HPLC with fluorimetric detection. Fresenius' Journal of Analytical Chemistry. 1986;324(3-4): 354.

14.     G. Rathinavel, P.B. Mukherjee, J. Valarmathy, L. Samueljoshua, M. Ganesh, T. Sivakumar and T. Saravanan. A Validated RP-HPLC Method for Simultaneous Estimation of Cefixime and Cloxacillin in Tablets. E-Journal of Chemistry. 2008;5(3): 648-651.

15.     Dhandapani B, Thirumoorthy N, Shaik HR, Kotaiah MR and Anjaneyalu N. Method development and validation for the simultaneous estimation of ofloxacin and ornidazole in tablet dosage form by RP-HPLC. Int J Pharm Sci Res. 2010;1(1):78-83.

16.     Premanand DC, Senthilkumar KL, Senthilkumar B, Thirumurthy R. A validated RP-HPLC method for simultaneous estimation of Nitazoxanide and Ofloxacin in pharmaceutical formulation. Der Chemica Sinica. 2010;1(2):1-5.

17.     Jovanovic SE, Agbaba D, Stakic DZ and Vladimirov S, HPTLC determination of ceftriaxone, cefixime and cefotaxime in dosage forms, Journal of Pharma. Biomed Analysis. 1998; 18: 893-898.

18.     Nanda R.K., Gaikwad J. and Prakash A. Simultaneous Spectrophotometric Estimation of Cefixime and Ornidazole in Tablet Dosage Form, International Journal of Pharm Tech Research. 2009;1(3): 488-491.

19.     Kasture VS, Bhagat AP, Puro NC. Spectrophotometric method for simultaneous estimation of ofloxacin and ornidazole in Tablet Dosage Form. Ind Drugs. 2004; 41: 51-53.

20.     Bhusari KP, Chaple DR. Simultaneous spectrophotometric estimation of ofloxacin and ornidazole in Tablet dosage form. Asian J Res Chem. 2009; 2: 60-62.

21.     Khoo LE, Abdalla AS, Bahruddin A, Abdussalam AM, Hassan Y. Simultaneous determination of ofloxacin and ornidazole in pharmaceutical preparations by capillary zone electrophoresis. Biomedical Chromatogram. 2009; 23: 1283-90.

22.     Mali Audumbar, Jadhav Santosh, Tamboli Ashpak, Bathe Ritesh, Patil Manoj. Development and Validation of UV-Spectrophotometric Method for the Estimation of Quinapril Hydrochloride in Bulk and In Its Formulation. World Journal of Pharmaceutical Research. 2015; 4(1): 1839-1846.

23.     Audumbar Digambar Mali, Ritesh Bathe, Manojkumar Patil and Ashpak Tamboli. Zero order and area under curve spectrophotometric methods for determination of Levocetirizine in pharmaceutical formulation. International Journal of Advances in Scientific Research. 2015; 1(06): 270-275.

24.     Mali Audumbar, Jadhav Santosh, Hake Gorakhnath, Tamboli Ashpak. Zero Order and Area under Curve Spectrophotometric Methods for Determination of Fluoxetine Hydrochloride in Pharmaceutical Formulation. Pharmatutor Magazine. 2015; 3(6): 49-54.

25.     Mali Audumbar Digambar, Hake Gorakhnath, Patil Manojkumar, Bathe Ritesh, Tamboli Ashpak. Zero Order and Area under Curve Spectrophotometric Methods for Determination of Ampicillin Trihydrate in Pharmaceutical Formulation. GCC Journal of Science and Technology. 2015; 1(1): 6-12.

26.     Audumbar Digambar Mali. Estimation of Domperidone in Bulk and Formulation byFirst Order Derivative Area under Curve UV-Spectrophotometry Methods. International Journal of Pharmacy and Technology. 2015; 7(1): 8040-8048.

27.     Mali Audumbar Digambar, Hake Gorakhnath and Patil Manojkumar. Zero order and area under curve spectrophotometric methods for determination of Paracetamol in pharmaceutical formulation. Bulletin of Advanced Scientific Research. 2015; 1(3): 102-105.

28.     Audumbar Digambar Mali. Simultaneous Determination Of Carvedilol and Hydrochlorothiazide in Pharmaceutical Dosage Form by First Order Derivative UV Spectrophotometry. International Journal of Pharmacy and Pharmaceutical Sciences. 2015; 7(9): 371-374.

29.     Audumbar Digambar Mali, Swapnil More, Shashikant Jokar, Rupali Hirve, Jyotiram Sawale. Zero Order and Area under Curve Spectrophotometric Methods for Determination of Amoxicillin Trihydrate in Pharmaceutical Formulation. International Journal of Analytical, Pharmaceutical and Biomedical Sciences. 2015; 4(7): 81-89.

30.     Mali Audumbar Digambar, Jadhav Santosh, Tamboli Ashpak, and Kargane Vijay. Development And Validation of UV Spectrophotometric Estimation of Lisinopril Dihydrate In Bulk And Tablet Dosage Form Using Area Under Curve Method. World Journal of Pharmacy and Pharmaceutical Sciences. 2014; 4(2): 589-596.

31.     International Conference on Harmonization (ICH) of Technical Requirements for the registration of Pharmaceuticals for Human use, Validation of Analytical Procedures Methodology. ICH-Q2 (R1), Geneva.1996, 1-8.

 

 

 

 

Received on 22.03.2016       Accepted on 15.04.2016     

© Asian Pharma Press All Right Reserved

Asian J. Pharm. Res. 2016; 6(2): 100-106

DOI: 10.5958/2231-5691.2016.00017.4